<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01838941</url>
  </required_header>
  <id_info>
    <org_study_id>RPGDN001</org_study_id>
    <nct_id>NCT01838941</nct_id>
  </id_info>
  <brief_title>Betaine and Peroxisome Biogenesis Disorders</brief_title>
  <official_title>A Pilot, Open Label Trial Assessing the Safety and Efficacy of Betaine in Children With Peroxisome Biogenesis Disorders.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital &amp; Medical Center Omaha</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McGill University Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PBD are a rare group of inherited disorders due to the failure to form functional
      cellular peroxisomes. Most patients have progressive hearing and visual loss, leading to
      deafness and blindness, as well as neurological deterioration. There are no therapies for
      this disorder. A misfolded protein with residual function, PEX1-Gly843Asp, represents one
      third of all mutant alleles. Using patient cell lines with this mutation, we reported the
      recovery of peroxisome functions by treatment with Betaine, acting as a nonspecific chemical
      chaperone for the misfolded PEX1 protein. Betaine, or trimethylglycine, is a Health Canada
      and FDA approved orphan drug for the treatment of homocystinuria and is used by us safely and
      regularly in genetic medicine. We will perform a 6 month pilot study with 12 patients to test
      the hypothesis that Betaine, at recommended doses, can recover peroxisome biochemical
      functions in blood.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peroxisome biogenesis disorders (PBD) are a group of inherited conditions caused by faulty
      assembly of peroxisomes, structures located inside cells that regulate levels of important
      fats and lipids in the body. When there is faulty peroxisome assembly, as in PBD, these
      important fats and lipids either accumulate or are not made. There is no specific treatment
      for these disorders, and management is supportive. In order to complement existing supportive
      therapies, physicians and researchers are still actively looking for new treatments acting on
      the root cause of PBD: the peroxisome function. To identify drugs that help recover
      peroxisome function a group of scientists developed a laboratory-based research test aimed at
      reviewing the activity of the large number of potential treatments. Using this test, they
      have uncovered that Betaine can improve the function of the peroxisome, when the defect is
      caused by a PEX1-Gly843Asp mutation, and as such may improve the overall health of child
      suffering from PBD.

      Betaine is a medication already available as a powder for oral solution, for another rare
      disease. It is approved in many countries, including Health Canada for Canada and the Food
      and Drug Administration for the USA. Paediatric genetic physicians are used to prescribing
      this medication and know it well.

      At the current stage of scientific knowledge, it is a critical next step to evaluate the
      benefit of betaine in children having a PBD due to a PEX1-Gly843Asp mutation, to ensure that
      the medication is safe and to measure the level of improvement of the function of the
      peroxisome.

      Thus, the principal objective of the study is to determine the improvement in the key
      peroxisome functions (plasma very long chain fatty acid profiles red cell plasmalogen levels,
      plasma pipecolic acid levels and plasma bile acid profiles). Another objective is to measure
      the growth of your child and his / her development.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peroxisome Biochemical Functions as Measured by Plasma Very Long Chain Fatty Acid</measure>
    <time_frame>6 months</time_frame>
    <description>C26/C22 ratio in plasma is a recognized biomarker for very long chain fatty acid (normal range: 0.002-0.018). It was measured twice before the beginning of treatment and measured once at the end.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Developmental Status</measure>
    <time_frame>6 months</time_frame>
    <description>Denver Developmental Screening Test expressed in years and months.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Peroxisome Biogenesis Disorders</condition>
  <arm_group>
    <arm_group_label>Betaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Betaine will be given orally to all participants and dose will be adjusted to body weight.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betaine</intervention_name>
    <description>Betaine will be given orally (mixed with food or dissolved in water, juice, milk, or formula) or through gastrostomy tube as follows:
6 g/day in children &lt; 30 kg, in 3 divided doses (2 g at meal time)
12 g/day in children &gt; 30 kg, in 4 divided doses (3 g at meal time and bed time).</description>
    <arm_group_label>Betaine</arm_group_label>
    <other_name>Cystadane®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females

          -  Any age

          -  Peroxisome Biogenesis Disorder (PBD) confirmed by biochemical analysis of at least two
             peroxisomal enzyme parameters:

               -  Elevated plasma VLCFA (C26/22) &gt; 0.02

               -  Elevated plasma branched chain pristanic acid &gt; 0.3 μg/ml

               -  Reduced red blood cell plasmalogen levels (C16:0DMA/C16:0 Fatty acid) &lt; 0.07

          -  PBD clinical syndromes: neonatal adrenoleukodystrophy (NALD) or infantile Refsum
             disease (IRD)

          -  Genotype PEX1-G843D/G843D, PEX1-G843D/I700fs, or PEX1-G843D and any second PEX1
             mutation that is predicted to be null

          -  Expected survival of at least 6 months

        Exclusion Criteria:

          -  Genotypes other than PEX1 G843D/G843D, PEX1-G843D//I700fs, or PEX1-G843D and any
             second PEX1 mutation that is predicted to be null

          -  Patient already treated with betaine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy Braverman, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Children's Hospital, MUHC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montreal Children's Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Zhang R, Chen L, Jiralerspong S, Snowden A, Steinberg S, Braverman N. Recovery of PEX1-Gly843Asp peroxisome dysfunction by small-molecule compounds. Proc Natl Acad Sci U S A. 2010 Mar 23;107(12):5569-74. doi: 10.1073/pnas.0914960107. Epub 2010 Mar 8.</citation>
    <PMID>20212125</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2013</study_first_submitted>
  <study_first_submitted_qc>April 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2013</study_first_posted>
  <results_first_submitted>June 8, 2015</results_first_submitted>
  <results_first_submitted_qc>May 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 28, 2016</results_first_posted>
  <last_update_submitted>May 20, 2016</last_update_submitted>
  <last_update_submitted_qc>May 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Center</investigator_affiliation>
    <investigator_full_name>Nancy Braverman</investigator_full_name>
    <investigator_title>Associate Professor, Depts. of Human Genetics and Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Peroxisome Biogenesis Disorder</keyword>
  <keyword>PBD</keyword>
  <keyword>neonatal adrenoleukodystrophy</keyword>
  <keyword>infantile Refsum disease</keyword>
  <keyword>PEX1 mutation</keyword>
  <keyword>Betaine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Peroxisomal Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Betaine</title>
          <description>Betaine will be given orally to all participants and dose will be adjusted to body weight.
Betaine: Betaine will be given orally (mixed with food or dissolved in water, juice, milk, or formula) or through gastrostomy tube as follows:
6 g/day in children &lt; 30 kg, in 3 divided doses (2 g at meal time)
12 g/day in children &gt; 30 kg, in 4 divided doses (3 g at meal time and bed time).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants seen at research site; evaluation included physical examination, collection of medical history, measure of hematology, laboratory, and biochemical parameters.</population>
      <group_list>
        <group group_id="B1">
          <title>Betaine</title>
          <description>Betaine will be given orally to all participants and dose will be adjusted to body weight.
Betaine: Betaine given orally (mixed with food or dissolved in water, juice, milk, or formula) or through gastrostomy tube:
6 g/day in children &lt; 30 kg, in 3 divided doses (2 g at meal time)
12 g/day in children &gt; 30 kg, in 4 divided doses (3 g at meal time and bed time).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Participants (n = 12) were seen at the research site at the beginning (baseline visit) and at the end of the study (6-month visit).
Physical examination was done at baseline and final visits. Medical history was collected and updated at that time.
Hematology, laboratory, and biochemical parameters were measured at baseline and 6 months.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.75" lower_limit="0.92" upper_limit="31.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mutation status</title>
          <description>Homozygous (mild form of PBD) or hemizygous for PEX1 G843D mutation (intermediate form of PBD)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>PEX1 G843D homozygous mutation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PEX1 G843D/null mutations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peroxisome Biochemical Functions as Measured by Plasma Very Long Chain Fatty Acid</title>
        <description>C26/C22 ratio in plasma is a recognized biomarker for very long chain fatty acid (normal range: 0.002-0.018). It was measured twice before the beginning of treatment and measured once at the end.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Betaine</title>
            <description>Betaine will be given orally to all participants and dose will be adjusted to body weight.
Betaine will be given orally (mixed with food or dissolved in water, juice, milk, or formula) or through gastrostomy tube as follows:
6 g/day in children &lt; 30 kg, in 3 divided doses (2 g at meal time)
12 g/day in children &gt; 30 kg, in 4 divided doses (3 g at meal time and bed time).</description>
          </group>
        </group_list>
        <measure>
          <title>Peroxisome Biochemical Functions as Measured by Plasma Very Long Chain Fatty Acid</title>
          <description>C26/C22 ratio in plasma is a recognized biomarker for very long chain fatty acid (normal range: 0.002-0.018). It was measured twice before the beginning of treatment and measured once at the end.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.180" lower_limit="0.027" upper_limit="0.301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.188" lower_limit="0.059" upper_limit="0.286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Developmental Status</title>
        <description>Denver Developmental Screening Test expressed in years and months.</description>
        <time_frame>6 months</time_frame>
        <population>The Denver Developmental Screening Test was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Betaine</title>
            <description>Betaine will be given orally to all participants and dose will be adjusted to body weight.
Betaine: Betaine will be given orally (mixed with food or dissolved in water, juice, milk, or formula) or through gastrostomy tube as follows:
6 g/day in children &lt; 30 kg, in 3 divided doses (2 g at meal time)
12 g/day in children &gt; 30 kg, in 4 divided doses (3 g at meal time and bed time).</description>
          </group>
        </group_list>
        <measure>
          <title>Developmental Status</title>
          <description>Denver Developmental Screening Test expressed in years and months.</description>
          <population>The Denver Developmental Screening Test was not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Betaine</title>
          <description>Betaine will be given orally to all participants and dose will be adjusted to body weight.
Betaine: Betaine will be given orally (mixed with food or dissolved in water, juice, milk, or formula) or through gastrostomy tube as follows:
6 g/day in children &lt; 30 kg, in 3 divided doses (2 g at meal time)
12 g/day in children &gt; 30 kg, in 4 divided doses (3 g at meal time and bed time).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear infection/Otitis media</sub_title>
                <description>Ear infection/Otitis media in 2 participants; duration: 5 days to 1 month.</description>
                <counts group_id="E1" events="9" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye discharge</sub_title>
                <description>Eye discharge in 1 participant.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Diarrhea in 2 participants; duration: between 1 to 6 days.</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gas</sub_title>
                <description>Gas in 1 participant; duration: 6 days.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Constipation in 4 participants; duration: 6 to 9 days.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Vomiting in 1 participant; duration: 11 days.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <description>Decreased appetite in 2 participants; duration: up to 2 months</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Upset stomach</sub_title>
                <description>Upset stomach in 1 participant; duration: 1 month</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <description>Dry mouth in 1 participant; duration: 1 week.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Fatigue in 3 participants; duration: 2 weeks to 4 months.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral syndrome</sub_title>
                <description>Viral syndrome in 3 participants; duration: approx. 5 days.</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated INR levels</sub_title>
                <description>Elevated INR levels in 1 participant</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Increase in seizure activity</sub_title>
                <description>Increase in seizure activity in 1 participant; duration: unknown</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Febrile seizure</sub_title>
                <description>Febrile seizure in 1 participant; duration: 1 day</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Croup</sub_title>
                <description>Croup in 1 participant; duration: 1 day.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <description>Respiratory tract infection in 2 participants; duration: 7 to 10 days.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Change in body odor (skin, urine, and/or breath)</sub_title>
                <description>Change in breath in 2 participants; duration: up to 6 months Change in body odor (metallic smell) in 1 participant; duration: 2 months and a half.
Change in urine odor in 2 participants; duration: 2 months.</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Large intra- and inter-individual variations in peroxisome functions, variation in phenotype severity, variation in age, number of participants; blood metabolite markers may be less sensitive than direct measurements of cell responses.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Nancy Braverman, Associate Professor, Human Genetics and Pediatrics</name_or_title>
      <organization>McGill University Health Centre</organization>
      <phone>(514) 934-1934 ext 23404</phone>
      <email>nancy.braverman@mcgill.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

